Gilbert & Cook Inc. Purchases 2,198 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Key Points

• Gilbert & Cook Inc. increased its stake in Ascendis Pharma A/S by 49.7%, purchasing 2,198 additional shares to bring its total holdings to 6,619 shares valued at approximately $1,032,000.
• Several institutional investors have also increased their positions in Ascendis Pharma, with JPMorgan Chase & Co. raising its stake by 94.4% in the last quarter, now owning 77,427 shares worth about $10.7 million.
• Ascendis Pharma A/S reported a quarterly loss of ($1.66) earnings per share, missing analysts' expectations, despite achieving revenue of $123.97 million for the quarter, exceeding expectations of $98.56 million.

Gilbert & Cook Inc. lifted its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 49.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,619 shares of the biotechnology company's stock after purchasing an additional 2,198 shares during the quarter. Gilbert & Cook Inc.'s holdings in Ascendis Pharma A/S were worth $1,032,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. JPMorgan Chase & Co. increased its stake in Ascendis Pharma A/S by 94.4% in the 4th quarter. JPMorgan Chase & Co. now owns 77,427 shares of the biotechnology company's stock valued at $10,659,000 after buying an additional 37,593 shares during the last quarter. Corient Private Wealth LLC bought a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at about $450,000. Pursue Wealth Partners LLC bought a new position in shares of Ascendis Pharma A/S in the 1st quarter valued at about $226,000. Nomura Asset Management Co. Ltd. grew its position in shares of Ascendis Pharma A/S by 13.9% in the 4th quarter. Nomura Asset Management Co. Ltd. now owns 20,506 shares of the biotechnology company's stock valued at $2,823,000 after acquiring an additional 2,506 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Ascendis Pharma A/S by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 57,077 shares of the biotechnology company's stock valued at $7,858,000 after acquiring an additional 629 shares during the period.

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock traded down $0.84 during trading hours on Friday, reaching $167.47. The company's stock had a trading volume of 421,932 shares, compared to its average volume of 412,063. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $183.00. The company has a market capitalization of $10.24 billion, a P/E ratio of -26.67 and a beta of 0.38. The stock's fifty day simple moving average is $170.63 and its two-hundred day simple moving average is $155.66.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The business had revenue of $123.97 million for the quarter, compared to analysts' expectations of $98.56 million. As a group, research analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Morgan Stanley initiated coverage on shares of Ascendis Pharma A/S in a report on Thursday, July 3rd. They set an "overweight" rating and a $250.00 target price for the company. Evercore ISI boosted their target price on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. Cantor Fitzgerald restated an "overweight" rating and issued a $200.00 target price on shares of Ascendis Pharma A/S in a research report on Monday, May 12th. Royal Bank Of Canada boosted their target price on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. Finally, Wedbush upped their price objective on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. One analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, Ascendis Pharma A/S has an average rating of "Moderate Buy" and an average target price of $223.07.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.